Key Words: Endometriosis, GnRH-a, goserelin, Zoladex, estrogen, sex-steroid add-back therapy,

Size: px
Start display at page:

Download "Key Words: Endometriosis, GnRH-a, goserelin, Zoladex, estrogen, sex-steroid add-back therapy,"

Transcription

1 FERTLTY AND STERLTY Copyright 1995 American Society for Reproductive Medicine Vol. 64, No. 5, November 1995 Printed on acid free paper in U. S. A. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis*+ Pentti Kiilholma, M.D.:j: Risto Tuimala, M.D. Seppo Kivinen, M.D. Mikko Korhonen, M.D.** Eelis Hagman, M.D.i'i' University Hospital of Turku, Turku; University Hospital of Tampere, Tampere; University Hospital of Kuopio, Kuopio; Central Hospital of Kanta-Hame, Hameenlinna; and Central Hospital of Etela-Pohjanmaa, Seinajoki, Finland Objective: To investigate whether the addition oflow-dose estrogen-p combination hormone replacement therapy () to GnRH agonist (GnRH-a) treatment for endometriosis reduces the pharmacologic side effects of such treatment without reducing efficacy and to determine the endocrinologic changes during treatment. Design: Prospective, randomized, double-blind, placebo-controlled, comparative study of two drug regimens: 3.6 mg goserelin acetate in a 28-day SC depot formulation once monthly for 6 months plus either a combination of 2 mg 17 {3-E2 and 1 mg norethisterone acetate (NET) 1 mg or matching placebo tablets once daily for 6 months. Setting: Multicenter study in three tertiary referral centers at university teaching hospitals and two central hospitals. Patients: Women with laparoscopically confirmed symptomatic endometriosis were included in the study. Results: Of the total of 19 patients screened, 93 were recruited and 88 patients were randomized to either the or the placebo group. Four women were withdrawn because of various medical reasons, and 76 patients were followed-up for a total of 12 months. n terms of efficacy, there was no difference between the two drug regimens for objective or subjective response. There were significantly less postmenopausal symptoms in the patients treated with goserelin plus compared with those treated with goserelin plus placebo. Conclusion: Goserelin diminished significantly the symptoms and laparoscopic scores of endometriosis. The addition of did not reduce the efficacy of goserelin but diminished the postmenopausal symptoms during treatment. Fertil Steri1995;64:93-8 Key Words: Endometriosis, GnRH-a, goserelin, Zoladex, estrogen, sex-steroid add-back therapy, Kliogest Since 1982, when the first clinical trial in humans using GnRH agonist (GnRH-a) for the treatment of Received November 14, 1994; revised and accepted May 12, * Presented at the Second nternational Symposium on GnRH analogues in Cancer and Human reproduction, Geneva, Switzerland, November 7 to 1, 199 and at the X World Congress of Gynecology and Obstetrics, Singapore, September 15 to 2, t Supported by Zeneca Pharma, Helsinki, Finland. :j: Department of Obstetrics and Gynecology, University Hospital of Turku. Reprint requests: Pentti Kiilholma, M.D., Department of Obstetrics and Gynecology, University Hospital ofturku, FN-252 Turku, Finland (FAX: ). endometriosis was reported (1), multiple studies have demonstrated consistent gonadal suppression with both subjective and objective improvement in patients with endometriosis (2, 3). Several randomized studies have shown that GnRH-a are at least as Department of Obstetrics and Gynecology, University Hospital of Tampere. Department of Obstetrics and Gynecology, Central Hospital of Kanta-Hame. ** Department of Obstetrics and Gynecology, University Hospital of Kuopio. tt Department of Obstetrics and Gynecology, Central Hospital of Etela-Pohjanmaa. Vol. 64, No.5, November 1995 Kiilholma et a. GnRH-a versus GnRH-a plus in endometriosis 93

2 effective as danazol in reducing subjective symptoms and in achieving resolution of endometriotic deposits (4-7). Furthermore, it has been suggested that the hypoestrogenic side effects of GnRH-a can be reduced or inhibited by the addition of estrogen-p to the treatment regimen without any subsequent loss in efficacy (8). The purpose of the present study was to investigate whether low-dose estrogen-p combination hormone replacement therapy () reduces the hypoestrogenic side effects of GnRH-a without compromising the efficacy of the GnRH-a in the treatment of endometriosis and to determine the endocrinologic changes. Patients MATERALS AND METHODS Women with endometriosis confirmed by laparoscopy before randomization underwent subjective assessments of pelvic symptoms: dysmenorrhea, dyspareunia, and pelvic pain. The severity of each symptom was graded on a scale of to 3 (absent, mild, moderate, and severe) and summed to give a total pelvic symptoms score. Only symptomatic patients with total pelvic symptoms score of ;;:::3 with or without infertility were included in the study. Patients also were examined to assess pelvic tenderness and induration, the severity of which also was graded on a scale of to 3. Endometriosis was confirmed by laparoscopy within 3 months before initiation of treatment. No attempt for endometriosis reduction other than biopsy was made. At laparoscopy the disease was staged according to the revised American Fertility Society (AFS) classification (9) and the Additive Diameter of mplants (1). Study Design After the confirmation of endometriosis by laparoscopy, patients were randomized to a 6-month treatment with 3.6 mg goserelin acetate in a 28-day SC depot formulation (Zoladex; Zeneca Pharmaceuticals, Macclesfield, United Kingdom) plus either a combination of 2 mg 17(3-E2 and 1 mg norethisterone acetate (NET; Kliogest; Novo Nordisk AS, Bagsvrerd, Denmark) or placebo once daily for 6 months. The trial medication was initiated at visit 1, and visits 2 to 6 were at 1, 3, 6, 9, and 12 months, respectively. Therapy was started during menstruation, preferably on the 1st day. Assessment of pelvic symptoms and physical examination were carried out pretreatment, at 1, 3 and 6 months after the start of treatment, and at 3 and 6 months post-treatment, i.e., 9 and 12 months after initiation of the treatment. The score montha Figure 1 The pelvic symptoms scores before and after 1, 6, and 12 months of treatment with goserelin acetate plus (1lT) and goserelin acetate plus placebo (li.\1). Values are means with range (upper and lower limits). P <.1: 6-month values significantly different from pretreatment values within both treatment groups. patients completed a menstrual, hot flush, and bleeding chart daily throughout the study until the first menstrual period after cessation of therapy. The investigator summarized the findings from the chart on the record forms at each visit. A second-look laparoscopy was performed 1 month after the last goserelin acetate injection. Total Additive Diameter of mplants and revised AFS scores were calculated at the post-treatment laparoscopy and compared with those at entry. An objective response was defined as a decrease of ;;::: 5% in the revised AFS score for peritoneal plus ovarian endometriosis. A decrease of <5% or withdrawal from the study for any reason at any time before the second laparoscopy assessment was considered as a treatment failure. Objective progression was defined as an increase of ;;:::25% in the score. The date of resumption of menses after cessation of treatment was documented. The written approval for the study was obtained from the Ethics Committee of each hospital. nformed consent was obtained from all patients and documented. Patients were provided with written information about the trial in the form of a patient information sheet. Hormone Measurements Serum concentrations of LH and FSH were determined fluoroimmunometrically by using commercial kits (DELFA LH and FSH) supplied by Wallac Co. (Turku, Finland). Serum 17 (3-E2 was measured using RA supplied by Baxter Dade Ag (Dudingen, Switzerland). Serum hormone concentrations were determined pretreatment, at 4 and 12 weeks during the treatment period, at the end of the treatment period, and at 3 and 6 months post-treatment. 94 Kiilholma et al. GnRH-a versus GnRH-a plus in endometriosis Fertility and Sterility

3 A.CDr. 3 *** GOSERELlN+ B mm *** GOSEREUN+PLACEBO them did not fulfill the criteria (pelvic symptom score <3). n addition, five further patients were protocol violators and they were excluded. Thus, 88 women were randomized to trial medication. Forty-three patients aged 2 to 48 years (mean 32 years) were allocated to goserelin acetate plus treatment and 45 patients aged 21 to 47 years (mean 34 years) were allocated to goserelin acetate plus placebo regimen. Patient demographics did not differ between groups in terms of age, weight at entry and at 6 months, average duration of menses, number of pregnancies, or number of live births. Altogether, 76 patients completed the study protocol at 12 months (35 in the goserelin acetate plus group and 41 in the goserelin acetate plus placebo group). Two patients discontinued the treatment because of side effects that were considered to be related to the treatment. One of them (goserelin acetate plus placebo) experienced severe depression and the other one had continuous bleeding (goserelin GOSERELlN+ GOSERELlN+PLACEBO A % 1 *** *** Figure 2 Total revised AFS (A) and total Additive Diameter of mplants (B) scores before (!ill) and 6 months after (l1li) treatment with goserelin acetate plus (bars at left) and goserelin plus placebo (bars at right). Values are means ± SEM. ***p <.1: significance of differences between and 6 months within treatment groups Statistical Analysis The comparison of objective response between the groups was made by using analysis of variance (generallinear method) and t-test using least significant difference method, which was used to test means between treatment groups. The t-test was used in the within-group test (Ho hypothesis was that the difference between the means between visits is ). For subjective scoring, the analysis of variance was used. The comparison of side effects was made by using the analysis of variance (between groups) and X 2 (within groups). For the comparison of hormone levels and restarting of menstruation the analysis of variance (general linear method) and t-test was used. All statistical analyses were performed by Research nternational Finland Oy, (Helsinki, Finland). RESULTS The total number of patients recruited was 93. Altogether, 19 patients were screened, but 16 of monilia B % *** *** montha Figure 3 The percentage of patients reporting hot flushes (A) and sweating (B) before and after 1, 3, 6, 9, and 12 months of treatment with goserelin acetate plus (!ill) and goserelin acetate plus placebo (l1li). **p =.3, ***p <.1: significance of differences between the treatment groups. Vol. 64, No.5, November 1995 Kiilholma et al. GnRH-a versus GnRH-a plus in endometriosis 95

4 % of pat. 1 - fll fl ** *** F F e.& o. 19 o l p F!i. 1 p % V 1. % f g.al ::ij 6 p P 12 months L- Figure 4 The percentage of patients reporting hot flushes ( no flushes; El less than once daily; i!! one to three times daily; i!! more than three times daily) before and after 1, 6, and 12 months of treatment with goserelin acetate plus and goserelin acetate plus placebo. **p <.1, ***p <.1: significance of differences between the treatment groups. acetate plus ). Three women had pregnancy confirmed during the post-treatment follow-up period. Two patients underwent surgery for endometriosis, one woman started hormonal contraception, two women were treated with hormonal or VF therapy for infertility, one patient needed hormonal therapy for a disease other than endometriosis, and one patient did not return. Forty and 43 patients with and without, respectively, completed the 6-month active treatment period. All patients showed subjective improvement on goserelin acetate therapy. The response was equally good in patients with or without (P = not significant [NS]). The pelvic symptoms score decreased from 4.7 and 4.7 in goserelin acetate plus and goserelin acetate plus placebo patients to.9 and.5 after 6 months, respectively (Fig. 1). There already was a marked fall in the score after 4 weeks of treatment. The within-group difference from pretreatment to 6-month treatment in both treatment groups was highly significant (P <.1). The scores six months after the cessation of the treatment were still significantly lower compared with those at entry, being 1.4 and 1.6 (Fig. 1). The objective response in terms of changes in total revised AFS and total Additive Diameter ofmplants scores with and without was also comparable (Fig. 2). Total revised AFS score decreased statistically significantly (P <.1) from 22.3 and 19.9 on goserelin acetate plus and goserelin acetate plus placebo, respectively, to 1.7 and 9.2 at secondlook laparoscopy. There were no significant differences between the two drug regimens. Total Additive Diameter of mplants score showed a similar decrease (P <.1) from 31.8 and 33.6 mm to 12.1 and 8. mm, respectively. Sixty-seven percent of patients allocated to goserelin acetate plus therapy and 73% ofthe patients treated with goserelin acetate plus placebo showed an objective response. The results were 26 and 22 in terms of treatment failure and 7 and 5 for objective progression, respectively. The difference between the two drug regimens was not statistically significant. The percentage of patients reporting hot flushes and sweating before and after 1, 3, 6, 9, and 12 months of treatment with both drug regimens is shown in Figure 3. The difference between patients treated with or without in addition to GnRH-a is statistically significant after treatment of 1 (P =.3), 3, and 6 months (P <.1). Hot flushes were reported more frequently by the patients receiving goserelin acetate plus placebo than by those receiving, as seen in Figure 4. The difference was significant (P <.1) after 4 weeks of trial medication and highly significant at 6 months (P <.1). There was no difference between the mean onset times of menstruation after the last injection of goserelin acetate depot. t was 69.5 days in the patients treated with goserelin acetate plus and 69.4 days in those treated with goserelin acetate plus placebo. Serum LH, FSH, and E2 concentrations (mean :±: SEM) before, during, and after treatment are shown in Figure 5. Serum LH and FSH levels were low during the treatment period. A statistically sig- 96 Kiilholma et a!. GnRH-a versus GnRH-a plus in endometriosis Fertility and Sterility

5 A lull 12 i 1 1 i! 8 " E 4 > 2 B lull 1 i " 8 8 " 8 :: e 4 E S > 2 C nmoll,5,4.,3 Ci 2 E ' j, *.* \, - - "t- - - ;",,,,,,, 12 months J 12 months Pllml 12 1 O r 'r-O o months Figure 5 Serum LH (A), FSH (B), and E 2, (C) levels before, during, and after treatment with goserelin acetate plus (_) and goserelin acetate plus placebo (A) at, 1, 6, and 12 months. Values are means ± SEM. *p <.5, ***p <.1: significance of differences between the treatment groups. nificant difference between the two drug regimens was noted in serum FSH levels, which were lower after 1, 3, and 6 months in the patients treated with goserelin acetate plus than goserelin acetate plus placebo (P <.5 at 1 and 6 months; P <.1 at 3 months between the groups). Serum E2 levels were low during the treatment period, but they were significantly higher in the patients treated with goserelin acetate plus than those with goserelin acetate plus placebo (P <.1) at 4 weeks and at 3 and 6 months The within-group differences in hormone serum concentrations from pretreatment to 6-months treatment were highly significant (P =.1) except for E2 in the goserelin acetate plus group (P =.29) (Fig. 5). For the 23 patients wishing to become pregnant, there were three pregnancies (13%). DSCUSSON Although several studies have been published investigating the use of so-called add-back therapy together with GnRH-a in the various gynecological conditions (11-13), there is little information on the use of such combinations in the patients with endometriosis. The first studies were performed by combining GnRH-a with progestins. n one study (14), patients treated with a combination of goserelin acetate and medroxyprogesterone acetate (MPA) had significantly less hot flushes than patients given goserelin acetate alone and no bone loss was seen. Unfortunately, this regimen failed to reduce significantly the subjective symptoms of endometriosis and there was no improvement in the revised AFS scores in contrast to a 5% to 6% improvement with the GnRH-a alone. n another study (15), NET, a progestin with less estrogenic activity than MPA, was combined with the GnRH-a histrelin. The addition of NET did not affect adversely the efficacy of histrelin on endometriosis. This combination was associated with a lower incidence of side effects than in the control group given histrelin alone. The reduction in vasomotor symptoms occurred despite a reduction in serum E2 concentrations into the castrate range and was dependent on the dose of NET. Progestins, however, are not ideal add-back regimens. They may result in symptoms similar to those of premenstrual syndrome and adversely affect lipid profile (11, 13). A recent study reported by Edmonds and Howell (16) combining goserelin acetate with.25 mg 17(3- E2 via an estraderm patch resulted in smaller loss in bone mineral density than in patients treated with goserelin acetate alone; however, the dose of estrogen was too low to prevent bone loss completely. Some of the pharmacologic side effects were reduced and efficacy was identical in both treatment groups. The present study using a larger dose of 17 (3-E2 showed that the long-acting GnRH-a goserelin acetate significantly diminished symptoms and laparoscopic scores of endometriosis and that combination of goserelin acetate and low-dose does not prevent the beneficial effect of GnRH-a on endometriosis. Based on these findings and the recent report of Leather et al (17), we believe that in conjunction with long-term GnRH-a therapy should reduce the risk of osteoporosis. Vol. 64, No.5, November 1995 Kiilholma et al. GnRH-a versus GnRH-a plus in endometriosis 97

6 Serum LH, FSH, and E2 values in the patients without were consistent with a previous report (18). The fall in serum LH levels after GnRH-a was the same in the placebo and groups and serum FSH levels were only moderately higher in the patients who received placebo than in those who received. Unlike most protocols using GnRH-a with addback therapy, we initiated at the beginning of GnRH-a treatment rather than after a period of several months GnRH-a alone. The relatively modest reduction of E2 in women with is not what most would consider to be adequate for the treatment of endometriosis (19). There are, however, suggestions that cyclical changes of ovarian hormones rather than their absolute concentrations are important in the genesis of menstrually related disorders such as endometriosis (2). Because it is known that low-dose continuous estrogen-p combination therapy causes endometrial atrophy and accordingly may result in regression of endometrial implants, we chose this combination for the add-back treatment regimen. t is possible that, without cyclical elevations in E2, the E2 levels in the patients treated with are below the estrogen "threshold" for endometriotic implants (19). n our study, GnRH-a appeared to be well tolerated by the patients. Only two patients discontinued the treatment for drug-related side effects. Even if postmenopausal symptoms caused by goserelin acetate without were quite bothersome for many patients they were, however, willing to continue the treatment. We think that patient compliance is better with long-acting depot implants than with frequently administered GnRH-a formulations. Goserelin acetate also provides a more steady hypothalamic down-regulation and ovarian suppression (18). n conclusion, the present study demonstrates that the long-acting GnRH-a goserelin acetate significantly diminishes symptoms and laparoscopic scores of endometriosis. The combination of goserelin acetate and low-dose estrogen-p add-back therapy while preventing postmenopausal-type symptoms during the treatment does not affect adversely its efficacy. Acknowledgment. The authors appreciate the assistance of Mr. Oli Lehti, M.Sc. (Pharm.) in the preparation of this manuscript. REFERENCES 1. Meldrum DR, Chang RJ, Vale W, Rivier J, Judd HL. "Medical oophorectomy" using a long-acting GnRH agonist: a possible new approach to the treatment of endometriosis. J Clin Endocrinol 1982;54: Lemay A, Maheux R, Faure N, Jean C, Fazekas ATA. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertil Steril1984;41: Erickson LD, Ory SJ. GnRH analogues in the treatment of endometriosis. Obstet Gynecol Clin North Am 1989; 16: Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicentre doubleblind comparative clinical trial. N Engl J Med 1988;318: Shaw RW, Zoladex Endometriosis Study Team. A randomized, comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Fertil Steril 1992; 58: Kennedy SH, Williams la, Brodribb J, Barlow DH, Shaw RW. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril 199;53: Rock JA, Truglia JA, Caplan RJ, Study Group. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstet Gynecol 1993; 82: Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166: The American Fertility Society. Revised American Fertility Society Classification of Endometriosis: Fertil Steril 1985;43: Doberl A, Bergqvist A, Jeppsson S, Koskimies A, Ronnberg L, Segerbrand E, et al. Regression of endometriosis following shorter treatment with or lower dose of danazol. Acta Obstet Gynecol Scand Supp1984;123: Barbieri RL. Gonadotropin releasing hormone agonists and estrogen-progestogen replacement therapy. Am J Obstet Gynecol 199; 162: Judd HL. Gonadotropin-releasing hormone agonists: strategies for managing the hypoestrogenic effects of therapy. Am J Obstet Gynecol 1992; 166: Lemay A, Surrey ES, Friedman AJ. Extending the use of gonadotropin-releasing hormone agonists: the emerging role of steroidal and non-steroidal agents. Fertil Steril 1994; 61: Cedars M, Meldrum DR, Judd HL. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonists plus medroxyprogesterone acetate. Obstet Gynecol 199; 75: Surrey ES, Gambone JC, Lu JKH, Judd HL. The effect of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Fertil Steril199;53: Edmonds DK, Howell R. Can hormone replacement therapy be used during medical therapy of endometriosis? Br J Obstet Gynaecol 1994; 11 Suppl 1: Leather AT, Studd JWW, Watson NR, Holland EFN. The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy. Obstet Gynecol 1993;81: Venturini PL, Fasce V, Constantini S, Anserini P, Cucuccio S, de Cecco L. Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results. Fertil Steril 199; 54: Barbieri RL. Gonadotropin-releasing hormone agonists: treatment of endometriosis. Clin Obstet Gynecol 1993;36: Reid BA, Gangar KF, Beard RW. Severe endometriosis treated with gonadotrophin releasing hormone agonist and continuous combined hormone replacement therapy. Br J Obstet Gynaecol 1992; 99: Kiilholma et al. GnRH-a versus GnRH-a plus in endometriosis Fertility and Sterility

Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study*

Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study* .. FERTILITY AND STERILITY Copyright 99 The American Fertility Society Vol. 59, No., March 99 Printed on acid-free paper in U.S.A. Buserelin acetate in the treatment of pelvic pain associated with minimal

More information

Henk R. Franke, M.D., Ph.D., a Peter H. M. van de Weijer, M.D., Ph.D., b Ton M. M. Pennings, M.D., c and Marius J. van der Mooren, M.D., Ph.D.

Henk R. Franke, M.D., Ph.D., a Peter H. M. van de Weijer, M.D., Ph.D., b Ton M. M. Pennings, M.D., c and Marius J. van der Mooren, M.D., Ph.D. FERTILITY AND STERILITY VOL. 74, NO. 3, SEPTEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Gonadotropin-releasing

More information

CY Tse, AMK Chow, SCS Chan. Introduction

CY Tse, AMK Chow, SCS Chan. Introduction Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate

More information

Gynecology-endocrinology

Gynecology-endocrinology Gynecology-endocrinology FERTILITY AND STERILITY Vol. 64, No.3, September 1995 Copyright C> 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Gonadotropin-releasing

More information

ORILISSA (elagolix) oral tablet

ORILISSA (elagolix) oral tablet ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

Goserelin (Zoladex*) depot in the treatment of endometriosist

Goserelin (Zoladex*) depot in the treatment of endometriosist FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Goserelin (Zoladex*) depot in the treatment of endometriosist Romeo P. Reichel, M.D.* Karl-W.

More information

A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis

A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident

More information

Palm Beach Obstetrics & Gynecology, PA

Palm Beach Obstetrics & Gynecology, PA Palm Beach Obstetrics & Gynecology, PA 4671 S. Congress Avenue, Lake Worth, FL 33461 561.434.0111 4631 N. Congress Avenue, Suite 102, West Palm Beach, FL 33407 Endometriosis The lining of the uterus is

More information

MANAGEMENT OF REFRACTORY ENDOMETRIOSIS

MANAGEMENT OF REFRACTORY ENDOMETRIOSIS (339) MANAGEMENT OF REFRACTORY ENDOMETRIOSIS Serdar Bulun, MD JJ Sciarra Professor and Chair Department of Ob/Gyn Northwestern University ENDOMETRIOSIS OCs Teenager: severe dysmenorrhea often starting

More information

Int J Clin Exp Med 2013;6(7): /ISSN: /IJCEM Yi Han 1,2, Shi-En Zou 1, Qi-Qi Long 1, Shao-Fen Zhang 1

Int J Clin Exp Med 2013;6(7): /ISSN: /IJCEM Yi Han 1,2, Shi-En Zou 1, Qi-Qi Long 1, Shao-Fen Zhang 1 Int J Clin Exp Med 2013;6(7):583-588 www.ijcem.com /ISSN:1940-5901/IJCEM1306010 Original Article The incidence and characteristics of uterine bleeding during postoperative GnRH agonist treatment combined

More information

me LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS

me LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS FERTILITY AND STERILITY Copyright c 980 The American Fertility Society Vol. 33,, JanuaEY 980 Printed in U.S.A. me LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS W. PAULDMOWSKI, M.D.,.PH.D.*

More information

Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy*

Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy* Gynecology-endocrinology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U S. A. Treatment of hirsutism with a gonadotropin-releasing hormone agonist

More information

The effect of gonadotropin-releasing hormone agonist on thyroid-stimulating hormone and prolactin secretion in adult premenopausal women

The effect of gonadotropin-releasing hormone agonist on thyroid-stimulating hormone and prolactin secretion in adult premenopausal women FERTILITY AND STERILITY Vol. 64, No.4, October 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. The effect of gonadotropin-releasing hormone agonist

More information

Orilissa (elagolix) NEW PRODUCT SLIDESHOW

Orilissa (elagolix) NEW PRODUCT SLIDESHOW Orilissa (elagolix) NEW PRODUCT SLIDESHOW Introduction Brand name: Orilissa Generic name: Elagolix Pharmacological class: GnRH antagonist Strength and Formulation: 150mg, 200mg; tabs Manufacturer: AbbVie

More information

Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis

Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis Original Article Obstet Gynecol Sci 2016;59(1):32-38 http://dx.doi.org/10.5468/ogs.2016.59.1.32 pissn 2287-8572 eissn 2287-8580 Effects of different add-back regimens on hypoestrogenic problems by postoperative

More information

GnRH agonist and antagonist: Options for endometriosis pain treatment

GnRH agonist and antagonist: Options for endometriosis pain treatment Thomas Jefferson University Jefferson Digital Commons Department of Obstetrics and Gynecology Faculty Papers Department of Obstetrics and Gynecology November 2006 GnRH agonist and antagonist: Options for

More information

The biology of menstrually related. Ovulation Suppression of Premenstrual Symptoms Using Oral Contraceptives REPORTS. Patricia J.

The biology of menstrually related. Ovulation Suppression of Premenstrual Symptoms Using Oral Contraceptives REPORTS. Patricia J. REPORTS Ovulation Suppression of Premenstrual Symptoms Using Oral Contraceptives Patricia J. Sulak, MD Abstract Managing premenstrual symptoms at the most fundamental level necessitates careful consideration

More information

t Funded by a grant from TAP Pharmaceuticals, Deerfield, Illinois.

t Funded by a grant from TAP Pharmaceuticals, Deerfield, Illinois. FERTILITY AND STERILITY Vol. 63, No.4, April 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Prolonged gonadotropin-releasing hormone agonist treatment

More information

The Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage

The Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage The Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage Pages with reference to book, From 30 To 32 Sertac Batioglu, Havva Celikkanat, Mustafa Ugur, Leyla Mollamahmutoglu, Huseyin

More information

Endometriosis Treatment & Management Medscape

Endometriosis Treatment & Management Medscape Endometriosis Treatment & Management Medscape Updated: Apr 25, 2016 Author: G Willy Davila, MD; Chief Editor: Michel E Rivlin, MD more... Approach Considerations The dependence of endometriosis on the

More information

Department of Gynecologic Surgery, Maternité Jeanne de Flandres, Lille, France

Department of Gynecologic Surgery, Maternité Jeanne de Flandres, Lille, France FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Dienogest is as effective

More information

Endometriosis: treatment with gonadotropinreleasing hormone agonist Buserelin*t

Endometriosis: treatment with gonadotropinreleasing hormone agonist Buserelin*t FERTILITY AND STERILITY Copyright 989 The American Fertility Society Printed in U.S.A. Endometriosis: treatment with gonadotropinreleasing hormone agonist Buserelin*t Anton M. H. W. Franssen, M.D.:j: Frank

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Gonadotropin Releasing Hormone (GnRH) Analogs Drugs: Eligard (leuprolide acetate), Firmagon (degarelix), Lupaneta Pack (leuprolide acetate and norethindrone), Lupron Depot (leuprolide

More information

Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation

Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation SCIENTIFIC PAPER Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation O. Shawki, MD, A. Peters, DO, S. Abraham-Hebert,

More information

Gonadotropin Releasing Hormone (GnRH) Analogs Drug Class Prior Authorization Protocol

Gonadotropin Releasing Hormone (GnRH) Analogs Drug Class Prior Authorization Protocol Gonadotropin Releasing Hormone (GnRH) Analogs Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been

More information

Endometriosis. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax

Endometriosis. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax Endometriosis What you need to know 139 Dumaresq Street Campbelltown Phone 4628 5292 Fax 4628 0349 www.nureva.com.au September 2015 What is Endometriosis? Endometriosis is a condition whereby the lining

More information

Endometriosis. Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University.

Endometriosis. Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University. Endometriosis Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University. Endometriosis Definition: Ectopic Endometrial Tissue True Incidence Unknown:? 1-5% Does NOT Discriminate by

More information

This case represents 1 of the challenges of

This case represents 1 of the challenges of OBG MANAGEMENT BY DAVID ADAMSON, MD Minimal to mild endometriosis: 4 treatment options Since even limited disease can cause infertility or substantial pain, it should be taken as seriously as severe endometriosis.

More information

PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.

PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW. PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas

More information

Department of Obstetrics and Gynaecology, Royal Surrey County Hospital, Guildford, United Kingdom

Department of Obstetrics and Gynaecology, Royal Surrey County Hospital, Guildford, United Kingdom FERTILITY AND STERILITY Vol. 62, No.4, October 1994 Copyright c 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Prospective, randomized, double-blind, controlled trial of laser

More information

Department of Obstetrics and Gynecology, Chosun University School of Medicine, Gwangju, Korea

Department of Obstetrics and Gynecology, Chosun University School of Medicine, Gwangju, Korea J MM pissn: 2288-6478, eissn: 2288-6761 Journal of Menopausal Medicine 2016;22:174-179 Original Article Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist

More information

Pre and post surgical medical therapy. Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy

Pre and post surgical medical therapy. Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy Pre and post surgical medical therapy Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy introduction A disease is an open problem when two conditions are nor satisfied: The

More information

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

When acute therapies of menstrually

When acute therapies of menstrually PREVENTIVE TREATMENT OF MENSTRUALLY RELATED MIGRAINE * Stephen D. Silberstein, MD, FACP ABSTRACT Preventive treatment of menstrually related migraine (MRM) is initiated when acute therapies fail to provide

More information

LUTEINIZED UNRUPTURED FOLLICLE SYNDROME: A SUBTLE CAUSE OF INFERTILITY*

LUTEINIZED UNRUPTURED FOLLICLE SYNDROME: A SUBTLE CAUSE OF INFERTILITY* FERTILITY AND STERILITY Copyright c 1978 The American Fertility Society Vol. 29, No.3, March 1978 Printed in U.S.A. LUTEINIZED UNRUPTURED FOLLICLE SYNDROME: A SUBTLE CAUSE OF INFERTILITY* JAROSLA V MARIK,

More information

Original Policy Date

Original Policy Date MP 5.01.30 Implantable Hormone Pellets Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy created with literature search/12:2013 Return

More information

Endometriosis Samuel J. Chantilis, M.D.

Endometriosis Samuel J. Chantilis, M.D. Endometriosis Samuel J. Chantilis, M.D. I. INTRODUCTION Endometriosis is the presence and growth of glands and stroma identical to the lining of the uterus in an aberrant location. Common symptoms of endometriosis

More information

Sexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist

Sexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with

More information

2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:

2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug: 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: Name of Study Drug: Volume: Abbott-43818 (ABT-818) leuprolide acetate for depot suspension (Lupron Depot ) Name of

More information

understanding endometriosis Authored by Dr KT Subrayen Sponsored by

understanding endometriosis Authored by Dr KT Subrayen Sponsored by understanding endometriosis Authored by Dr KT Subrayen Sponsored by in this booklet What is Endometriosis? 1 What causes Endometriosis? 3 What does Endometriosis look like? 4 Common symptoms of Endometriosis

More information

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date:

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date: Clinical Policy: (Zoladex) Reference Number: ERX.SPA.145 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A.

Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A. Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A. Ott's Research Institute of Obstetrics, Gynecology and Reproductology,

More information

Addressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue

Addressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue Addressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue Objectives Describe the multiple symptoms of endometriosis and its varied presentation

More information

Endometriosis. *Chocolate cyst in the ovary

Endometriosis. *Chocolate cyst in the ovary Endometriosis What is endometriosis? Endometriosis is a common condition in young women. It's chronic, painful, and it often progressively gets worse over the time. *Chocolate cyst in the ovary Normally,

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

Endometriosis-associated pelvic pain: evidence for an association between the stage of disease and a history of chronic pelvic pain*

Endometriosis-associated pelvic pain: evidence for an association between the stage of disease and a history of chronic pelvic pain* F ERTILITY AND STERILITY Copyright " 1997 American Society for Reproductive Medicine Published by Elsevier Science Inc. Vo!. 68, No. 1, J uly 1997 Printed on acid -free paper in U. S. A. Endometriosis-associated

More information

CLEAR COVERAGE HYSTERECTOMY CHECKLISTS

CLEAR COVERAGE HYSTERECTOMY CHECKLISTS CLEAR COVERAGE HYSTERECTOMY CHECKLISTS Click on the link below to access the checklist sheet. Abnormal Uterine Bleeding Adenomyosis Chronic Abdominal or Pelvic Pain Endometriosis Fibroids General Guidelines

More information

Neodymium: VAG laser hysteroscopy in large submucous fibroids

Neodymium: VAG laser hysteroscopy in large submucous fibroids FERTILITY AND STERILITY Copyright 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Neodymium: VAG laser hysteroscopy in large submucous fibroids Jacques Donnez, M.D., Ph.D.*

More information

Int J Clin Exp Med 2016;9(10): /ISSN: /IJCEM

Int J Clin Exp Med 2016;9(10): /ISSN: /IJCEM Int J Clin Exp Med 2016;9(10):19935-19943 www.ijcem.com /ISSN:1940-5901/IJCEM0027833 Original Article Clinical outcome of various regimens of gonadotropin-releasing hormone analogues after conservative

More information

Assisted Reproductive Technology (ART) / Infertility / Synarel (nafarelin)

Assisted Reproductive Technology (ART) / Infertility / Synarel (nafarelin) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.03 Subject: Synarel Page: 1 of 5 Last Review Date: September 15, 2016 Synarel Description Assisted

More information

Medical treatment for uterine fibroids

Medical treatment for uterine fibroids Medical treatment for uterine fibroids Prof Mary Ann Lumsden Prof of Gynaecology and Medical Education University of Glasgow Senior Vice President RCOG Conflict of Interest Chair, Guideline development

More information

D-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas

D-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas FERTILITY AND STERILITY Copyright" '1989 The American Fertility Society Vol. 52, No.3, Septemher 1989 Printed on acid-free paper in U.S.A. D-Trp-6-luteinizing hormone-releasing hormone microcapsules in

More information

Hormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare

Hormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest

More information

Use of Ovarian Suppression and Ablation in Breast Cancer Treatment

Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation

More information

Surgical treatment of endometriosis: location and patterns of disease at reoperation

Surgical treatment of endometriosis: location and patterns of disease at reoperation Surgical treatment of endometriosis: location and patterns of disease at reoperation Elizabeth Taylor, M.D., and Christina Williams, M.D. Division of Reproductive Endocrinology and Infertility, Department

More information

Premature Menopause : Diagnosis and Management

Premature Menopause : Diagnosis and Management Guideline Number 3 : August 2010 Premature Menopause : Diagnosis and Management Introduction : Premature menopause is a serious condition that affects young women and remains an enigma. The challenges

More information

Endometriosis and Infertility - FAQs

Endometriosis and Infertility - FAQs Published on: 8 Apr 2013 Endometriosis and Infertility - FAQs Introduction The inner lining of the uterus is called the endometrium and it responds to changes that take place during a woman's monthly menstrual

More information

Jinan Bekir, M.D. Amma Kyei-Mensah, M.D. Seang-Lin Tan, M.D.

Jinan Bekir, M.D. Amma Kyei-Mensah, M.D. Seang-Lin Tan, M.D. FERTILITY AND STERILITY Copyright ~ 1995 American Society for Reproductive Mediciue Vol. 64, No.4, October 1995 Printed on acid-free paper in U. S. A. Administration of progestogens to hasten pituitary

More information

GONADOTROPIN RELEASING HORMONE ANALOGS

GONADOTROPIN RELEASING HORMONE ANALOGS UnitedHealthcare Commercial Medical Benefit Drug Policy GONADOTROPIN RELEASING HORMONE ANALOGS Policy Number: PHA025 Effective Date: March 1, 2019 Table of Contents Page COVERAGE RATIONALE... 1 U.S. FOOD

More information

Is the endometriosis recurrence rate increased after ovarian hyperstimulation?

Is the endometriosis recurrence rate increased after ovarian hyperstimulation? Is the endometriosis recurrence rate increased after ovarian hyperstimulation? Thomas M. D Hooghe, M.D., Ph.D., Bénédicte Denys, M.D., Carl Spiessens, Ph.D., Christel Meuleman, M.D., and Sophie Debrock,

More information

LOW RESPONDERS. Poor Ovarian Response, Por

LOW RESPONDERS. Poor Ovarian Response, Por LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients

More information

The pharmacological management of ENDOMETRIOSIS

The pharmacological management of ENDOMETRIOSIS The pharmacological management of ENDOMETRIOSIS 18 Endometriosis is a gynaecological condition in which endometrial tissue is present outside the uterine cavity, causing cyclic symptoms and, often, reduced

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest

More information

Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis

Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis doi:10.1111/jog.13023 J. Obstet. Gynaecol. Res. Vol. 42, No. 9: 1152 1158, September 2016 Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis Yotaro

More information

Estrogens and progestogens

Estrogens and progestogens Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.

More information

M0BCore Safety Profile. Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR:

M0BCore Safety Profile. Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR: M0BCore Safety Profile Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR: 26.05.2014 4.3 Contraindications Hypersensitivity to GnRH, its analogues

More information

Drug Class Update: Drugs for Endometriosis

Drug Class Update: Drugs for Endometriosis Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596

More information

Hormonal Control of Human Reproduction

Hormonal Control of Human Reproduction Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with

More information

Ovarian response in three consecutive in vitro fertilization cycles

Ovarian response in three consecutive in vitro fertilization cycles FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in

More information

Clinica Ostetrica e Ginecologica I, Istituto Luigi Mangiagalli, University of Milano, Milan, Italy

Clinica Ostetrica e Ginecologica I, Istituto Luigi Mangiagalli, University of Milano, Milan, Italy FERTILITY AND STERILITY VOL. 80, NO. 2, AUGUST 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Comparison of a levonorgestrel-releasing

More information

Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome*t

Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome*t FERTILITY AND STERILITY Vol. 62, No. 5, November 1994 Copyright 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Depot leuprolide acetate with estrogen and progestin add-back

More information

Dr Mary Birdsall. Fertility Associates Auckland

Dr Mary Birdsall. Fertility Associates Auckland Dr Mary Birdsall Fertility Associates Auckland Period Problems Mary Birdsall Medical Director Fertility Associates Auckland Period Problems Basic Physiology No Periods Irregular Periods Heavy Periods

More information

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy? Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force

More information

Appendix: Reference Table of HT Brand Names

Appendix: Reference Table of HT Brand Names Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug

More information

Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain

Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain DOI: 10.1111/j.1471-0528.2009.02319.x www.bjog.org General gynaecology Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain

More information

Frequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.

Frequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc. Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses

More information

The Association of Minimally Invasive Gynecologic Surgeons dedicated to safe, state-of-the-art surgery and health life-styles for women of all ages

The Association of Minimally Invasive Gynecologic Surgeons dedicated to safe, state-of-the-art surgery and health life-styles for women of all ages The Association of Minimally Invasive Gynecologic Surgeons dedicated to safe, state-of-the-art surgery and health life-styles for women of all ages R. Wayne Whitted MD, MPH Paul A. Pietro MD Marina Santana

More information

Research Article. Comparative analysis of Yoga and clomiphene in infertile women. Richa Sharma 1, Himsweta Shrivastava 1, Arvind Kumar 2

Research Article. Comparative analysis of Yoga and clomiphene in infertile women. Richa Sharma 1, Himsweta Shrivastava 1, Arvind Kumar 2 Research Article Comparative analysis of Yoga and clomiphene in infertile women Richa Sharma 1, Himsweta Shrivastava 1, Arvind Kumar 2 1 Department of Obstetrics & Gynecology, University College of Medical

More information

Western Locality Shared care information ~ Gonadorelin Analogues (Gnrh)

Western Locality Shared care information ~ Gonadorelin Analogues (Gnrh) Western Locality Shared care information ~ Gonadorelin Analogues (Gnrh) Specialist: Please complete the Shared Care letter sending a request to GP (see bottom of the page) April 2013 GP: Please indicate

More information

GONADOTROPIN RELEASING HORMONE ANALOGS

GONADOTROPIN RELEASING HORMONE ANALOGS UnitedHealthcare Commercial Medical Benefit Drug Policy GONADOTROPIN RELEASING HORMONE ANALOGS Policy Number: 2017D0038H Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE...

More information

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists

More information

- Linzagolix overall efficacy and safety maintained or improved at week 24

- Linzagolix overall efficacy and safety maintained or improved at week 24 Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain - Linzagolix overall efficacy

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal myomectomy in leiomyoma management, 77 Abnormal uterine bleeding (AUB) described, 103 105 normal menstrual bleeding vs., 104

More information

https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm

https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm Journal Article Version This is the publisher s version. This version is defined in the NISO recommended practice RP-8-2008 http://www.niso.org/publications/rp/ Suggested Reference Brown, J., & Farquhar,

More information

Orals,Transdermals, and Other Estrogens in the Perimenopause

Orals,Transdermals, and Other Estrogens in the Perimenopause Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter

More information

Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy

Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human

More information

Picking the Perfect Pill How to Effectively Choose an Oral Contraceptive

Picking the Perfect Pill How to Effectively Choose an Oral Contraceptive Focus on CME at Queen s University Picking the Perfect Pill How to Effectively Choose an Oral Contraceptive By Susan Chamberlain, MD, FRCSC There are over 20 oral contraceptive (OC) preparations on the

More information

Key words: polycystic ovary syndrome, hypothalmic-pituitary-ovarian axes

Key words: polycystic ovary syndrome, hypothalmic-pituitary-ovarian axes Clin Pediatr Endocrinol 1999; 8(2), 77-84 Copyright 1999 by The Japanese Society for Pediatric Endocrinology Clinical, Hormonal, and Radiological Studies at Baseline, During and After Long Term GnRH Analog

More information

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years

More information

Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare

Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Carlo Alviggi The rational of Follicular synchronization

More information

Hormonal and biochemical changes during treatment of endometriosis with the luteinizing hormone-releasing

Hormonal and biochemical changes during treatment of endometriosis with the luteinizing hormone-releasing FERTILITY AND STERILITY Copyright" 199 The American Fertility Society Vol. 54, No.2, August 199 Printed on acid-free paper in U.S.A. Hormonal and biochemical changes during treatment of endometriosis with

More information

Infertility for the Primary Care Provider

Infertility for the Primary Care Provider Infertility for the Primary Care Provider David A. Forstein, DO FACOOG Clinical Associate Professor Obstetrics and Gynecology University of South Carolina School of Medicine Greenville Disclosure I have

More information

Breast Cancer Risk in Patients Using Hormonal Contraception

Breast Cancer Risk in Patients Using Hormonal Contraception Breast Cancer Risk in Patients Using Hormonal Contraception Bradley L. Smith, Pharm.D. Smith.bradley1@mayo.edu Pharmacy Ground Rounds Mayo Clinic Rochester April 3 rd, 2018 2017 MFMER slide-1 Presentation

More information

5. Summary of Data Reported and Evaluation

5. Summary of Data Reported and Evaluation 326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal

More information

Critical Appraisal of Endometriosis Management for Pain and Subfertility

Critical Appraisal of Endometriosis Management for Pain and Subfertility Critical Appraisal of Endometriosis Management for Pain and Subfertility N. F. Zuberi,J. H. Rizvi ( Department of Obstetrics and Gynaecology, The Aga Khan University, Karachi. ) Introduction Endometriosis

More information

How Neurosteroids Modulate Seizures in Children and Adults November 30, 2012

How Neurosteroids Modulate Seizures in Children and Adults November 30, 2012 How Neurosteroids Modulate Seizures in Children and Adults November 30, 2012 Page B. Pennell, MD Brigham and Women s Hospital Harvard Medical School Boston, MA American Epilepsy Society Annual Meeting

More information

Medical Management of Endometriosis: Novel Targets and Future Treatments Erkut Attar, M.D. PhD.

Medical Management of Endometriosis: Novel Targets and Future Treatments Erkut Attar, M.D. PhD. Medical Management of Endometriosis: Novel Targets and Future Treatments Erkut Attar, M.D. PhD. Istanbul University Istanbul Medical School Department of Obstetrics & Gynecology Division of Reproductive

More information

PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG. (goserelin)

PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG. (goserelin) ONC.000-092-861.10.0 PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG (goserelin) Name of the medicinal product Zoladex LA 10.8mg depot Qualitative and quantitative composition Goserelin acetate (equivalent to 10.8

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Drug Therapy Guidelines Applicable Injectable Fertility Medications: Bravelle, Cetrotide, Follistim AQ, Ganirelix, Gonal-F, human chorionic gonadotropin, leuprolide, Menopur, Novarel, Ovidrel, Pregnyl,

More information

Menopause & HRT. Matt McKenna Elliot Davis

Menopause & HRT. Matt McKenna Elliot Davis Menopause & HRT Matt McKenna Elliot Davis Menopause Before age 40: Premature Menopause After 12 months clinical diagnosis made Depletion of Ovarian Follicles Oestrogen Progesterone LH FSH Spontaneous Amemorrhoea

More information